Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of atezolizumab + bevacizumab versus sorafenib in hepatocellular carcinoma
2017-003691-31Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Atezolizumab + Bevacizumab with Sorafenib (2 arms). Primary endpoint: Overall survival. Started Mar 2018; status: completed.
02
Drugs
atezolizumabbevacizumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-003691-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003691-31.